ArticleAmerican journal of hematology2014
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.
Article in American journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.Haematologica · 2019Trial
- Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.Cancer · 2018Trial
- TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.British journal of haematology · 2015Trial
- Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.The Journal of clinical investigation · 2015Trial
- BRAF Mutations in Myeloid Neoplasms: Prevalence, Co-Mutation Landscape, and Clinical Outcomes-A Comprehensive Review.Biomedicines · 2026Review
- The role of RAS mutations in leukemia progression, differentiation, and drug resistance.Leukemia research reports · 2026Review
- Emperipolesis, not hemophagocytosis: chronic myelomonocytic leukemia with neoplasia-associated Rosai-Dorfman disease.International journal of hematology · 2026Article
- PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML.Blood neoplasia · 2025Article
- scTML: a pan-cancer single-cell landscape of multiple mutation types.Nucleic acids research · 2025Article
- Review
- Article
- Specific blood monocyte distribution in histiocytoses correlates with vascular involvement and disease activity.Haematologica · 2023Article
- Review
- Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing.The Journal of molecular diagnostics : JMD · 2020Article
- Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation.Haematologica · 2019Article
- Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection.Current hematologic malignancy reports · 2019Review
- Article
- Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated withBMJ case reports · 2019Article
- Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
The frequency of RAS mutations in chronic myelomonocytic leukemia (CMML) suggests that activation of the MAPK pathway is important in CMML pathogenesis. Accordingly, we hypothesized that mutations in other members of the MAPK pathway might be overrepresented in RAS(wt) CMML. We performed targeted next generation sequencing analysis on 70 CMML patients with known RAS mutation status. The study group included 37 men and 33 women with a median age of 67.8 years (range, 28-86 years). Forty patients were RAS(wt) and 30 were RAS(mut) ; the latter included KRAS = 17; NRAS = 12; KRAS + NRAS = 1. Five patients (7.1% of total group; 12.5% of RAS(wt) group) with RAS(wt) had kinase domain BRAF mutations. The BRAF mutations were of missense type and involved exon 11 in one patient and exon 15 in four patients. All BRAF(mut) patients had CMML-1 with low-risk cytogenetic findings. Two (40%) of the five patients with BRAF(mut) patients transformed to acute myeloid leukemia during follow-up. In summary, we demonstrate that a subset of patients with RAS(wt) CMML harbors BRAF kinase domain mutations that are potentially capable of activating the MAPK signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.